14-3-3σ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression by Qin, Li et al.
Oncotarget17726www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 14
14-3-3σ regulation of and interaction with YAP1 in acquired 
gemcitabine resistance via promoting ribonucleotide reductase 
expression
Li Qin1, Zizheng Dong1, Jian-Ting Zhang1
1 Department of Pharmacology and Toxicology and IU Simon Cancer Center, Indiana University School of Medicine, 
Indianapolis, Indiana, USA
Correspondence to: Jian-Ting Zhang, e-mail: jianzhan@iu.edu
Keywords: 14-3-3σ, gemcitabine resistance, ribonucleotide reductase, YAP1, gene expression
Received: September 05, 2015    Accepted: January 23, 2016    Published: February 15, 2016
ABSTRACT
Gemcitabine is an important anticancer therapeutics approved for treatment of 
several human cancers including locally advanced or metastatic pancreatic ductal 
adenocarcinoma (PDAC). Its clinical effectiveness, however, is hindered by existence 
of intrinsic and development of acquired resistances. Previously, it was found that 
14-3-3σ expression associates with poor clinical outcome of PDAC patients. It was 
also found that 14-3-3σ expression is up-regulated in gemcitabine resistant PDAC 
cells and contributes to the acquired gemcitabine resistance. In this study, we 
investigated the molecular mechanism of 14-3-3σ function in gemcitabine resistance 
and found that 14-3-3σ up-regulates YAP1 expression and then binds to YAP1 to 
inhibit gemcitabine-induced caspase 8 activation and apoptosis. 14-3-3σ association 
with YAP1 up-regulates the expression of ribonucleotide reductase M1 and M2, which 
may mediate 14-3-3σ/YAP1 function in the acquired gemcitabine resistance. These 
findings suggest a possible role of YAP1 signaling in gemcitabine resistance.
INTRODUCTION
Gemcitabine is a deoxycytidine analogue approved 
as the first-line chemotherapeutic drug for patients 
with locally advanced or metastatic pancreatic ductal 
adenocarcinoma (PDAC) [1, 2], one of the cancers having 
poorest prognosis with 5-year survival rate hovering only 
around 7% [3]. One of the major causes for the poor 
prognosis of PDAC is that it is intrinsically resistant or can 
acquire resistance to treatments including gemcitabine. 
Several molecular mechanisms of gemcitabine resistance 
have been identified including dysregulation of enzymes 
participating in gemcitabine metabolism, down-regulation 
of gemcitabine importer hENT1, down-regulation of rate-
limiting enzyme dCK, and up-regulation of gemcitabine 
target, ribonucleotide reductase M1 and M2 (RRM1 and 
RRM2) [4]. RRM has also been suggested to mediate 
C-MYC-dependent suppression of senescence [5].
It has also been shown previously that increased 14-
3-3σ expression associates with poor prognosis of PDAC 
[6, 7]. Recently, using a newly established gemcitabine 
resistant PDAC cell line, G3K derived from MiaPaCa-2 
cells via stepwise gemcitabine selections, we showed 
that 14-3-3σ expression is upregulated via epigenetic 
regulation and contributes to the acquired gemcitabine 
resistance in the gemcitabine-selected PDAC G3K cells 
[8]. In addition to the acquired gemcitabine resistance 
in PDAC cells, 14-3-3σ has been implicated in acquired 
doxorubicin resistance in breast cancer cells [9] and in 
cisplatin resistance of colon cancer cells [10]. Although 
14-3-3σ is known to belong to the highly conserved 14-
3-3 protein family that binds to many phosphoserine/
phosphothreonine proteins important in multiple 
biological processes such as signal transduction, cell 
cycle control, and survival [11-14], how its increased 
expression contributes to acquired drug resistance in 
general and gemcitabine resistance more specifically is 
largely unknown.
One of the phosphoserine/phosphothreonine 
protein partners of 14-3-3 family proteins is YAP1, a 
transcriptional coactivator in the Hippo/YAP pathway, 
which binds to and activates several transcription factors 
including Runx [15] and the highly conserved TEAD/
TEF transcription factors [16]. Once phosphorylated at 
a key serine residue (Ser127), YAP is sequestered in the 
cytoplasm by binding to 14-3-3 proteins, where it can no 
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longer function to promote target gene expression [17]. 
The crystal structure of 14-3-3σ/YAP1 phosphopeptide 
complex has been resolved at 1.15Å resolution, suggesting 
the interaction between YAP1 and 14-3-3σ [18]. In this 
study, we show that 14-3-3σ not only interacts with 
YAP1 but also regulates YAP1 expression. The increased 
14-3-3σ and YAP1 expression cooperates to contribute 
to the acquired gemcitabine resistance by inhibiting 
gemcitabine-induced caspase 8 activation possibly via 
up-regulating the expression of gemcitabine target protein 
RRM1 and RRM2.
RESULTS
YAP1 over-expression in G3K cells and its 
regulation by 14-3-3σ
To determine the potential role of YAP1 in 
14-3-3σ-mediated gemcitabine resistance, we first tested 
the level of total YAP1 and pYAP1 (Ser127 phosphorylated) 
in the parental MiaPaCa-2 and its gemcitabine resistant 
derivative G3K cells. As shown in Figure 1A, both 
YAP1 and pYAP1 proteins as well as YAP1 mRNA were 
significantly increased in G3K compared with MiaPaCa-2 
cells. Because 14-3-3σ expression is also up-regulated in 
G3K cells (Figure 1A), we next investigated if 14-3-3σ and 
YAP1 expression is related by first knocking down 14-3-
3σ in G3K cells and testing its effect on YAP1 expression. 
Figure 1B shows that 14-3-3σ knockdown significantly 
reduced YAP1 mRNA and protein levels. Ectopically 
over-expressing 14-3-3σ in the parental MiaPaCa-2 cells 
increased YAP1 mRNA and protein levels (Figure 1C). 
However, knocking down YAP1 had no effect on 14-3-3σ 
expression (Figure 1D). These findings suggest that 14-3-
3σ may regulate YAP1 expression but not vice versa.
Role of YAP1 in gemcitabine resistance
To determine if the increased YAP1 expression 
in G3K cells potentially contributes to the acquired 
gemcitabine resistance, we first knocked down YAP1 
in G3K cells followed by examining the difference in 
gemcitabine resistance using MTT assay. As shown in 
Figure 2A, YAP1 knockdown was successfully achieved 
without affecting 14-3-3σ expression and it dramatically 
reduced gemcitabine resistance of G3K cells. Unlike 14-3-
3σ over-expression in the parental MiaPaCa-2 cells, which 
resulted in increased gemcitabine resistance [8], ectopic 
over-expression of GFP-YAP1 in MiaPaCa-2 cells did not 
significantly influence the gemcitabine response (Figure 
2B). This observation is intriguing and inconsistent with 
our findings of YAP1 knockdown in G3K cells (Figure 2A).
Because YAP1 does not affect 14-3-3σ expression 
and the parental MiaPaCa-2 cells express little or no 
14-3-3σ, YAP1 over-expression alone in the parental 
MiaPaCa-2 cells may not be able to induce gemcitabine 
resistance if it works together with 14-3-3σ. To test this 
possibility, we took advantage of MiaPaCa-2 cells with 
stable over-expression of Flag-14-3-3σ (MiaPaCa-2/σ 
cells) and over-expressed GFP-YAP1 followed by survival 
assay in the presence of gemcitabine. As shown in Figure 
2C, over-expression of GFP-YAP1 significantly increased 
gemcitabine resistance of the MiaPaCa-2/σ cells. Thus, 
it is possible that YAP1 up-regulation contributes to the 
acquired gemcitabine resistance in G3K cells but it may 
require the presence of 14-3-3σ for this function.
14-3-3σ and YAP1 are inter-dependent in 
gemcitabine resistance
To further investigate if YAP1 requires 14-3-3σ in 
gemcitabine resistance, we transiently over-expressed 
GFP-YAP1 in MiaPaCa-2/σ cells followed by knocking 
down 14-3-3σ and survival assay. As shown in Figure 
3A, GFP-YAP1 over-expression significantly increased 
gemcitabine resistance of MiaPaCa-2/σ cells as expected. 
However, knocking down 14-3-3σ in MiaPaCa-2/σ cells 
with GFP-YAP1 over-expression completely eliminated 
the GFP-YAP1 over-expression-induced increase 
in gemcitabine resistance. It is noteworthy that the 
gemcitabine resistance of the 14-3-3σ knockdown cells 
is significantly lower than the control MiaPaCa-2/σ cells, 
demonstrating that the basal resistance induced by 14-3-
3σ over-expression in MiaPaCa-2/σ cells is reduced by 
14-3-3σ knockdown. This observation is consistent with 
our previous findings demonstrating the role of 14-3-3σ in 
gemcitabine resistance [8]. Similarly, YAP1 knockdown 
in MiaPaCa-2/σ cells also eliminated 14-3-3σ-induced 
gemcitabine resistance (Figure 3B). These findings suggest 
that YAP1 and 14-3-3σ may depend on each other for their 
functions in gemcitabine resistance.
To better address this hypothesis, we performed 
double knockdown experiments in G3K cells. As shown 
in Figure 4A, YAP1 and 14-3-3σ could be simultaneously 
knocked down. While knocking down 14-3-3σ or YAP1 
individually significantly reduced gemcitabine resistance 
of G3K cells, which is consistent with above findings, the 
double knockdown of 14-3-3σ and YAP1 did not result 
in further reduction in gemcitabine resistance. It is also 
noteworthy that the double knockdown did not affect the 
proliferation of G3K cells (data not shown). To ensure the 
above observation on gemcitabine resistance is not due to 
the use of a specific gemcitabine-selected cell line G3K, we 
performed a similar experiment using another PDAC cell 
line, ASPC-1, that expresses endogenous 14-3-3σ. As shown 
in Figure 4B, individual knockdowns of 14-3-3σ or YAP1 
resulted in significant reduction in gemcitabine resistance 
in ASPC-1 cells. Similar to G3K cells, double knockdown 
did not result in further reduction in gemcitabine resistance 
in ASPC-1 cells. Hence, 14-3-3σ and YAP1 may cooperate 
and require each other in pancreatic cancer cell survival 
against gemcitabine treatment.
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Figure 1: Expression and regulation of YAP1. A. Relative expression of YAP1 and pYAP1 in the parental MiaPaCa-2 and the 
gemcitabine-resistant derivative G3K cells. B–C. Effect of 14-3-3σ knockdown in G3K cells (B) or ectopic over-expression in MiaPaCa-2 
cells (C) on YAP1 and pYAP1 expression. D. Effect of YAP1 knockdown on 14-3-3σ expression. Actin was used as a loading control for 
Western blot (upper panels) and GAPDH was used as an internal control for real-time RT-PCR (lower panels). (n=3, **p<0.01)
Figure 2: Role of YAP1 in gemcitabine resistance. YAP1 siRNA was transiently transfected into G3K cells A. and GFP-YAP1 
cDNA was transiently transfected into MiaPaCa-2 cells B. or MiaPaCa-2 cells with stable 14-3-3σ expression (PaCa-2/σ) C. followed by 
Western blot analysis of YAP1 expression (upper panels) and survival analysis in the presence of gemcitabine using MTT assay (lower 
panels). RRF=relative resistance factor. Actin was used as a loading control for Western blot. (n=4, **p<0.01).
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14-3-3σ and YAP1 co-localize and interact with 
each other
To further test the cooperativity between 14-3-3σ 
and YAP1, we tested if they co-localize and possibly 
interact with each other. As shown in Figure 5A, both 
YAP1 and 14-3-3σ co-localized in the cytoplasm of 
G3K cells. We next performed co-immunoprecipitation 
analysis of 14-3-3σ and GFP-YAP1. As shown in 
Figure 5B, immunoprecipitation of 14-3-3σ resulted 
in co-precipitation of the phosphorylated YAP1. 
Immunoprecipitation of YAP1 also resulted in co-
precipitation of the ectopically over-expressed Flag-14-3-
3σ in G3K cells. Thus, 14-3-3σ likely can bind to and form 
a complex with pYAP1.
14-3-3σ and YAP1 protect against gemcitabine-
induced caspase-8 activation and apoptosis
To understand the mechanism of 14-3-3σ and 
YAP1-induced gemcitabine resistance, we tested if 
they protect PDAC cells against gemcitabine-induced 
apoptosis. As shown in Figure 6A, 14-3-3σ knockdown 
in G3K cells led to dose-dependent increase in 
gemcitabine-induced PARP-1 cleavage, an indicator 
of apoptosis. To confirm this finding and to ensure the 
effect was not due to off-target effect of the siRNA used, 
we performed apoptosis assay using the Cell Death 
Detection ELISA kit that quantifies the level of DNA 
fragmentation in a stable 14-3-3σ knockdown clone of 
G3K cells [8]. Figure 6B shows that the stable 14-3-
3σ knockdown using shRNA with a different targeting 
sequence from the siRNA used in the above experiments 
also significantly increased gemcitabine-induced 
apoptosis of G3K cells. Meanwhile, 14-3-3σ over-
expression in the parental MiaPaCa-2 cells eliminated 
gemcitabine-induced PARP1 cleavage (Figure 6C–6D). 
Similar to 14-3-3σ knockdown, YAP1 knockdown 
in G3K cells also led to dose-dependent increase in 
gemcitabine-induced PARP1 cleavage (Figure 6E). 
Thus, both YAP1 and 14-3-3σ helps protect PDAC cells 
against gemcitabine-induced apoptosis.
Figure 3: 14-3-3σ and YAP1 are inter-dependent in gemcitabine resistance. A. Effect of 14-3-3σ knockdown on gemcitabine 
resistance in MiaPaCa-2 cells with stable over-expression of 14-3-3σ and with YAP1 over-expression. B. Effect of YAP1 knockdown on 
gemcitabine resistance in MiaPaCa-2 cells with 14-3-3σ over-expression. Actin was used as loading control for Western blot analysis 
(upper panels). Lower panels show relative resistance factor (RRF) derived from dose-response curves from MTT assays. (n=3, **p<0.01, 
***p<0.001)
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Figure 4: Both 14-3-3σ and YAP1 are required for their role in gemcitabine resistance. G3K cells A. or ASPC-1 cells B. were 
transiently transfected with either scrambled (Scr) control siRNA, 14-3-3σ siRNA, and YAP1 siRNA alone, or co-transfected with both 
14-3-3σ and YAP1 siRNA simultaneously, followed by Western blot analysis of YAP1, 14-3-3σ and actin loading control or MTT assay in 
the presence of gemcitabine for analysis of gemcitabine resistance. (n=3-5, *p<0.05, **p<0.01, ***p<0.001, #p>0.05). Actin was used as 
a loading control for Western blot.
Figure 5: 14-3-3σ co-localization and interaction with YAP1. A. Co-localization of 14-3-3σ and YAP1 in G3K cells viewed using 
a confocal microscopy. B–C. Co-immunoprecipitation of 14-3-3σ and YAP1 in G3K cells. The ectopic GFP-YAP1 alone (B) or together 
with Flag-14-3-3σ (C) were over-expressed in G3K cells followed by immunoprecipitation with 14-3-3σ (B) or GFP (C) antibody or control 
normal IgG and Western blot analysis of pYAP1 or total YAP1 and 14-3-3σ.
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To investigate the specific apoptotic pathway 
that 14-3-3σ and YAP1 interferes, we first analyzed 
caspase-8 and caspase-9 activation following 
gemcitabine treatment in G3K cells. As shown in 
Figure 6, gemcitabine-induced caspase-8 cleavage and 
activation was dramatically elevated in YAP1 (Figure 
6E) and 14-3-3σ (Figure 6F) knockdown G3K cells and 
dramatically reduced in the 14-3-3σ-over-expressing 
MiaPaCa-2 cells (Figure 6C) compared with their 
respective control cells. However, caspase-9 activation 
was not affected (data not shown). It is noteworthy 
that G3K cells with stable 14-3-3σ knockdown using 
shRNA (Figure 6F) with different targeting sequence 
from siRNA (Figure 6A) also caused similar increase in 
gemcitabine-induced PARP1 cleavage, consistent with 
the findings shown in Figure 6B. Thus, likely 14-3-3σ 
and YAP1 may protect against gemcitabine-induced 
apoptosis by attenuating gemcitabine-induced caspase-8 
activation.
Role of 14-3-3σ and YAP1 in regulating RRM1 
and RRM2 expression
To understand how 14-3-3σ and YAP1 interfere with 
gemcitabine-induced apoptosis in PDAC cells, we resorted 
to the previously well known mechanisms of gemcitabine 
resistance, namely the over-expression of ribonucleotide 
reductase M1 and M2 (RRM1 and RRM2) [19, 20]. We 
have shown previously that the gemcitabine-resistant G3K 
cells also over-express RRM1 and RRM2 [8] (see also 
Figure 7A). To determine if there is a potential relationship 
between RRM1/RRM2 and 14-3-3σ/YAP1, we first tested 
RRM1 and RRM2 expression in MiaPaCa-2 cells with 
stable 14-3-3σ over-expression. As shown in Figure 7A, 
both RRM1 and RRM2 are up-regulated by 14-3-3σ over-
expression and down-regulated by 14-3-3σ knockdown 
using siRNA. Similarly, stable 14-3-3σ knockdown in G3K 
cells using shRNA also reduced expression of RRM1 and 
RRM2 (data not shown). Furthermore, 14-3-3σ knockdown 
also reduced the expression of both RRM1 and RRM2 
in G500 and G1K cells with intermediate gemcitabine 
resistance, which were produced during selection of G3K 
cells [8], suggesting that 14-3-3σ regulation of RRM1 and 
RRM2 expression is not specific to G3K cells. Similar to 
14-3-3σ knockdown, YAP1 knockdown also reduced the 
expression of both RRM1 and RRM2 in G3K cells (Figure 
7C). Thus, RRM1 and RRM2 may be the downstream 
mediators of 14-3-3σ/YAP1-induced gemcitabine resistance. 
More importantly, consistent with the prior findings that 
double knockdown of 14-3-3σ and YAP1 simultaneously 
did not further reduce gemcitabine resistance (Figure 4), 
simultaneous knockdown of 14-3-3σ and YAP1 fails to 
further reduce the expression of both RRM1 and RRM2 
compared with single knockdowns (Figure 7D). Thus, 
RRM1 and RRM2 may be the key downstream mediators 
of 14-3-3σ/YAP1-induced gemcitabine resistance.
Figure 6: Role of 14-3-3σ and YAP1 in gemcitabine-induced apoptosis and caspase-8 activation. A–B. Effect of 14-3-3σ 
knockdown on gemcitabine-induced apoptosis in G3K cells by determination of PARP1 cleavage using Western blot analysis (A) and using 
Cell Death Detection ELISA (B). (N=n, *p<0.05, **p<0.001). C–D. Effect of 14-3-3σ over-expression on gemcitabine-induced PARP1 
cleavage and caspase 8 activation. E–F. Effect of YAP1 (E) and 14-3-3σ (F) knockdown on gemcitabine-induced PARP1 cleavage and 
caspase 8 activation.
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DISCUSSION
While 14-3-3σ expression has been found to 
increase in cancer cells that have acquired drug resistant 
phenotype and contribute to the resistance, the detailed 
molecular mechanisms of its function in drug resistance 
remain elusive. Previously, it has been suggested that 
increased 14-3-3σ expression may cause resistance to 
drug-induced apoptosis [9], possibly by binding to and 
arresting cyclin B1 and CDC2 [21, 22] and pro-apoptotic 
proteins such as Bax and Bad [23, 24] in cytoplasm. 
Somatic knockout of 14-3-3σ in colon cancer cells has 
been shown to cause drug-induced mitotic catastrophe 
by reducing cellular ability to arrest in G2/M phase in 
response to DNA damage [21]. In this study, we identified 
a novel mechanism of 14-3-3σ-induced gemcitabine 
resistance in PDAC. As shown in Figure 7E, 14-3-3σ 
over-expression may promote YAP1 expression and 
interact with YAP1. The inter-dependent 14-3-3σ/YAP1 
interaction contributes to acquired gemcitabine resistance 
by attenuating gemcitabine-induced caspase-8 activation 
and apoptosis, possibly via enhancing the expression of 
RRM1 and RRM2, which are well known mechanisms in 
gemcitabine resistance.
In this study, we found that 14-3-3σ not only 
interacts and binds to YAP1, it also regulates YAP1 
expression. Because YAP1 mRNA level was also 
changed by 14-3-3σ, 14-3-3σ may regulate YAP1 
transcription. Although transcriptional regulation of 
YAP1 expression has not yet been studied, analysis of 
human YAP1 promoter sequence shows potential binding 
site for p53, AP-1, and c-Jun (unpublished observations). 
Because MiaPaCa-2 cells carry an inactive mutant 
p53, 14-3-3σ unlikely regulates YAP1 transcription 
via p53 although 14-3-3σ has been shown to positively 
regulate p53 [25]. Whether other transcription factors 
such as AP-1 and c-Jun mediates 14-3-3σ regulation of 
YAP1 transcription remain to be determined. We also 
found that pYAP1 was dramatically altered by 14-3-3σ. 
While the increased pYAP1 may be due to the increased 
total YAP1 expression, it is also possible that 14-3-3σ 
binding to pYAP1 stabilizes pYAP1, which contributes 
to the increased level of total YAP1 although this may be 
unlikely since 14-3-3σ knockdown did not reduce ectopic 
GFP-YAP1 (Figure 3A).
14-3-3σ and YAP1 over-expression-induced 
gemcitabine resistance appears to be via protecting cells 
against gemcitabine-induced caspase-8 activation and 
apoptosis. This observation is consistent with a previous 
report that gemcitabine induces caspase-8 activation 
in H292 cells and enhances cell sensitivity to Fas-
mediated cytotoxic activity [26]. Although it remains 
to be determined how gemcitabine induces caspase-8 
activation, it has also been reported that gemcitabine 
induces apoptosis in non-small cell lung cancer (NSCLC) 
cells by increasing expression of functionally active Fas 
(CD95, APO-1) and up-regulating Fas ligand (FasL) 
[26, 27]. However, it remains to be determined if 14-
Figure 7: Regulation of RRM1 and RRM2 expression by 14-3-3σ/YAP1. A. Western blot analysis of RRM1 and RRM2 
expression in the parental MiaPaCa-2 and gemcitabine resistant G3K cells and following 14-3-3σ over-expression in MiaPaCa-2 cells or 
14-3-3σ knockdown in G3K cells. B. Effect of 14-3-3σ knockdown on RRM1 and RRM2 expression in the intermediate resistant cell line 
G500 and G1K cells derived during stepwise selection of G3K cells. C. Effect of YAP1 knockdown on RRM1 and RRM2 expression in 
G3K cells. D. Effect of knocking down 14-3-3σ and YAP1 individually or both simultaneously on RRM1 and RRM2 expression in G3K 
cells. E. Schematic model of 14-3-3σ regulation and interaction with YAP1 in gemcitabine resistance.
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3-3σ/YAP1 up-regulation contributes to inhibition of 
gemcitabine-induced caspase-8 activation by affecting 
Fas or FasL.
One of the major targets of gemcitabine is RRM1 
and RRM2, which ensure sufficient supply of dNTP 
pool for DNA synthesis of proliferating cancer cells. 
Increased expression of RRM1 and RRM2 has been 
shown to contribute to acquired gemcitabine resistance 
[19, 20]. The finding that 14-3-3σ/YAP1 increases 
RRM1 and RRM2 expression is very intriguing while 
this finding suggests that RRM1 and RRM2 may be 
possible downstream mediators of 14-3-3σ/YAP1-
induced gemcitabine resistance. However, it remains 
to be determined how 14-3-3σ/YAP1 up-regulates 
RRM1 and RRM2 expression. Because both 14-3-3σ 
and YAP1 exert their functions by binding to other 
proteins, it is tempting to speculate that the increased 
14-3-3σ/YAP1 complex may increase RRM1 and RRM2 
stability. Because YAP1 binds to other transcription 
factors and regulate gene transcription, 14-3-3σ/YAP1 
complex may also regulate the transcription of RRM1 
and RRM2. One such potential transcription factor 
is NF-κB, which has been shown to regulate RRM2 
expression in gemcitabine-resistant human oral cancer 
KB cell line [28]. It has also been found that depleting 
glucose in culture media reduces RRM1 expression in 
PDAC cells [29]. However, it remains to be determined 
if 14-3-3σ/YAP1 participates in this regulation of 
RRM1 expression. Furthermore, CBL0137, a curaxin 
that inhibits chromatin remodeling complex FACT, 
sensitizes gemcitabine resistance in PDAC cells 
possibly by reducing RRM1 and RRM2 expression 
[30]. Interestingly, we previously observed that 14-
3-3σ up-regulation in the gemcitabine resistant G3K 
cells was due to reduced gene methylation. It is, thus, 
of interest to determine if CBL0137 affects 14-3-3σ 
expression by inhibiting chromatin remodeling, which 
in turn down-regulates RRM expression and increases 
gemcitabine sensitivity.
In summary, 14-3-3σ may have multiple 
mechanisms of function in contributing to drug 
resistance. This multifaceted property may be derived 
from its activity being able to interact with multiple 
proteins. However, it remains to be determined if 14-
3-3σ plays an important role in clinically acquired or 
intrinsic gemcitabine resistance in PDAC or clinical 
drug resistance in general although increased 14-3-3σ 
expression has been found in PDAC samples and appears 
to associate with poor prognosis of PDAC [6, 7]. It also 
remains to be determined if 14-3-3σ can be established 
as a potential target for drug discovery to sensitize drug-
resistant human cancers in combinational chemotherapy. 
We are currently working toward addressing these 
questions.
MATERIALS AND METHODS
Materials
Metafectene Pro transfection reagent was obtained 
from Biontex. siRNAs targeting 14-3-3σ (sc-29590), YAP1 
(sc-38637) were purchased from Santa Cruz Biotechnology. 
Antibodies against GFP (ab290), YAP1 (ab52771), pYAP1 
(ab76252) were from Abcam. Antibodies against 14-3-3σ 
(05-632), RRM1 (MABE567) and ChIP Assay kit (17-295) 
were purchased from EMD Millipore. Antibody against 
RRM2 was generated in-house [31]. Lipofectamine, 
pcDNA3.1(+) plasmid, and G418 were from Invitrogen. 
RNeasy Mini kit and Qiagen Blood and Cell Culture DNA 
Kit were from Qiagen. The iScriptTM cDNA synthesis kit 
and the SYBR Green PCR master mix were from Bio-Rad 
and Applied Biosystems, respectively. Gemcitabine were 
purchased from Besse Medical
Cell lines, cultures, and transfections
The gemcitabine resistant human PDAC cell lines 
G500, G1K and G3K cells were generated by stepwise 
selection of MiaPaCa-2 cells using increasing concentrations 
of gemcitabine and cultured in DMEM medium 
supplemented with 10% fetal bovine serum and 2.5% horse 
serum in the presence of gemcitabine as previously described 
[8]. Human PDAC cell line ASPC-1 was from ATCC and 
cultured in RPMI medium supplemented with 10% fetal 
bovine serum. The cell lines were authenticated by analysis 
of tandem repeat sequences on September 17, 2013.
For transient knockdown or over-expression of target 
genes, cells were plated in a six-well plate at a density of 
1.5-3×105 cells/well and cultured overnight in complete 
medium. About 60-120 pmol siRNAs of target genes or 
control scrambled siRNAs, or 1-2 μg of over-expressing 
plasmid of target genes or vector control plasmid were 
diluted in serum-free Opti-MEM medium and then 
transiently transfected into cells using Metafectene Pro 
transfection reagent as previously described [32].
For stable transfection, the cDNA of 14-3-3σ gene 
was engineered into pcDNA3.1(+) and transfected into 
MiaPaCa-2 cells using Lipofectamine. Stable clones were 
selected using 1 mg/ml G418 as previously described 
[9, 22]. The stable clones were maintained in complete 
medium supplemented with 200 μg/ml G418.
Similarly, the stable shRNA knockdown was 
generated as previously described [9, 22]. Briefly, G3K cells 
were transfected with pSilencer-σ (14-3-3σ shRNA cloned 
into pSilencer 3.1-H1neo vector) or scrambled shRNA 
construct [9, 22] using Lipofectamine followed by selection 
with 1 mg/ml G418 for 2 weeks. Individual clones were 
tested for 14-3-3σ knockdown and positive clones were 
propagated and maintained in complete DMEM medium.
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Cell lysate preparation and western blot
Cultured cells were harvested, washed with PBS, 
and lysed in TNN-SDS buffer (50 mM Tris-HCl, pH 7.4, 
150 mM NaCl, 0.5% Nonidet P-40, 50 mM NaF, 1 mM 
sodium orthovanadate, 1 mM dithiothreitol, 0.1% SDS, 
and 2 mM phenyl-methylsulfonyl fluoride) for 30 minutes 
at 4°C with constant agitation. The cell lysates were then 
sonicated briefly and followed by centrifugation (14,000×g 
at 4°C) for 15 minutes to remove insoluble materials. The 
protein concentrations of supernatants were measured by 
Bradford assay.
Cell lysates were separated by SDS-PAGE and 
transferred to a PVDF membrane followed by a 2-hr 
incubation in blocking solution (PBS-buffered saline 
containing 5% nonfat dried milk and 0.1% Tween 20) 
and a 2-hr incubation with primary antibodies. After 
extensive washes, immunoreactivity was detected with 
specific secondary antibodies conjugated to horseradish 
peroxidase. Signals were captured using ECL x-ray 
film.
Survival and apoptosis assay
Survival assay was performed as previously 
described using MTT colorimetric assay [7, 33]. Briefly, 
cells were seeded in 96-well plate at 2000-3000 cells/
well and cultured for 24 hrs followed by treatment 
with different doses of anticancer drugs and incubated 
continuously for 3 days followed by addition of MTT 
(5 mg/ml) to a final concentration of 0.5 mg/ml and 
incubation of the plates at 37°C for 4 hours. The OD
570nm
 
and OD
630nm
 were measured using an automated plate 
reader and analyzed using GraphPad Prism software 
to generate fitted curve and IC
50
. Relative resistance 
factor (RRF) is calculated using the following formula: 
RRF=IC
50(test)
/IC
50(control)
. For apoptosis assay, photometric 
enzyme immunoassay using a Cell Death Detection 
ELISA Plus kit (Roche Diagnostics, Indianapolis, IN) 
was performed for quantitative in vitro determination 
of cytoplasmic histone-associated DNA fragments and 
apoptosis as previously described [34].
Quantitative real-time RT-PCR
Quantitative RT-PCR was performed as 
described previously [35, 36]. Briefly, total RNA 
was extracted using RNeasy Mini Kit followed 
by reverse-transcription using iScriptTM cDNA 
synthesis kit and quantitative PCR using the SYBR 
Green PCR master mix. The primer pairs used are: 
5′-TAGGCGCTGTTCTTGCTCCAA-3′ (forward) and 
5′-ACCAGTGGTTAGGTGCGCTCA-3′ (reverse) for 14-
3-3σ; 5′-AAGAGCAGCGTGCCAGAGAT-3′ (forward) 
and 5′-ACACATCAAAGACCAGTCCTGATTAG-3′ 
(reverse) for RRM1; 5′-TCTGGCTTTCTTTGCAG 
CAA-3′ (forward) and 5′-CAGCGGGCTTCTGTAA 
TCTGA-3′ (reverse) for RRM2; 5′-CAGCAACTGC 
AGATGGAGAA-3′ (forward) and 5′-ACATCCCGGG 
AGAAGACACT-3′ (reverse) for YAP1; 5′-AAGGAC 
TCATGACCACAGTCCAT-3′ (forward) and 5′-CCAT 
CACGCCACAGTTTTC-3′ (reverse) for GAPDH.
Immunofluorescence and confocal  
microscope imaging
1-2 × 105 G3K cells were seeded on a glass 
coverslip in a six-well tissue culture plate. After the 
culture reaches confluence, the cells were washed 3 
times with ice-cold PBS and fixed with acetone/methanol 
(1:1) at room temperature for 15 min and incubated with 
blocking solution (3% bovine serum albumin in PBS) for 
1 h. The cells were then probed with primary antibody 
YAP1 (1:200) for 2 hrs followed by incubation with 
FITC-conjugated goat anti-rabbit IgG F(ab′)2fragment 
(Sigma) (1:1000 dilution) for 30 min. After being washed 
3 times with blocking solution, the cells were re-probed 
with another primary antibody 14-3-3σ (1:50) for 2 hrs 
followed by incubation with Alexa Fluor 647 dye (Life 
Technologies) for additional 30 min. Then, after being 
washed 3 times, the cell nucleus was counterstained with 
DAPI (25 μg/ml) for 20 min. The coverslips were then 
mounted on the slides before viewing with Olympus 2 
confocal microscope. The laser excitation lines are as 
follows: 405 nM for DAPI, 488 nM for FITC, and 635 
nM for Alexa Fluor 647. The image was then virtualized 
by Olympus Fluoview Ver.3.0 viewer (FV10-ASW 3.0 
viewer).
Immunoprecipitation assay
Immunoprecipitation was performed as previously 
described [37]. Briefly, 1 mg of cell lysates were first 
pre-cleaned by incubation with 1 μg of normal mouse 
IgG at 4 °C for 1 h, then mixed with 150 μL of protein 
G agarose beads (50% slurry) and incubated at 4 °C for 
2 hrs followed by centrifugation at 500× g for 5 min. 
The cleared supernatants were split into two equal parts 
incubated with either normal mouse IgG (as a negative 
control) or incubated with primary antibodies (anti-Flag, 
anti-YAP1, anti-pYAP1, or anti-GFP) at 4°C for 3 h, then 
each part was mixed with 50 μL of protein G agarose 
beads. After overnight incubation at 4 °C, the reaction 
was centrifuged to collect precipitates which were then 
washed five times with lysis buffer (50 mM Tris-HCl, 
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) 
before being subjected to SDS-PAGE analysis for Western 
blot analysis.
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